Fanny Polesso

发表

PD‐1‐specific “Blocking” antibodies that deplete PD‐1+ T cells present an inconvenient variable in preclinical immunotherapy experiments

M. Munks, A. Hill, Amy E. Moran, 2021, European journal of immunology.

PD-1 Specific ‘Blocking’ Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments

M. Munks, A. Hill, Amy E. Moran, 2020, bioRxiv.

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ

A. Weinberg, Amy E. Moran, Fanny Polesso, 2016, The Journal of Immunology.

This information is current as CD 8 T Cells In Situ Function of High-Affinity Tumor-Infiltrating Immunotherapy Expands and Maintains the

A. Weinberg, Amy E. Moran, Fanny Polesso, 2016 .

NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice.

Susan E. Murray, A. Hoffmann, Y. Koguchi, 2011, The Journal of clinical investigation.

OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function

Susan E. Murray, A. Weinberg, S. Murray, 2019, The Journal of Immunology.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

A. Coxon, Astrid A. Ruefli-Brasse, A. Slavin, 2008, Neoplasia.

Chd1 regulates open chromatin and pluripotency of embryonic stem cells

Michael T. McManus, João Ramalho-Santos, Eran Meshorer, 2009, Nature.

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Susan E. Murray, Reid F. Thompson, G. Thomas, 2022, Nature.

Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production

Susan E. Murray, D. Parker, Fanny Polesso, 2017, Scientific Reports.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist

A. Weinberg, Amy E. Moran, Fanny Polesso, 2018, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity.

S. Hammond, Amy E. Moran, Fanny Polesso, 2022, Journal of immunology.